{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:33:27Z","timestamp":1760056407479,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017412","name":"Becton Dickinson and Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.diagmicrobio.2022.115861","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T03:35:04Z","timestamp":1668656104000},"page":"115861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical performance evaluation of BD SARS-CoV-2 reagents for BD MAXTM System in asymptomatic individuals"],"prefix":"10.1016","volume":"105","author":[{"given":"Karen","family":"Yanson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Laviers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faten","family":"Suhaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Greeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Merryman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reda","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0001","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1473-3099(22)00070-6","article-title":"Transitioning to endemicity with COVID-19 research","volume":"22","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0002","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(21)02346-1","article-title":"Diagnostics for COVID-19: moving from pandemic response to control","volume":"399","author":"Peeling","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.883066","article-title":"As omicron takes hold and other new variants arise, COVID-19 testing remains the universally agreed tool to effect transition from pandemic to endemic state","volume":"10","author":"Miller","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3201\/eid2607.201595","article-title":"Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic","volume":"26","author":"Furukawa","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijid.2020.06.052","article-title":"Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis","volume":"98","author":"Kronbichler","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0006","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijid.2020.08.076","article-title":"Asymptomatic SARS Coronavirus 2 infection: invisible yet invincible","volume":"100","author":"Nikolai","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0007","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijid.2020.06.098","article-title":"The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review","volume":"98","author":"Al-Sadeq","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0008","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.7150\/ijbs.48991","article-title":"COVID-19: Insight into the asymptomatic SARS-COV-2 infection and transmission","volume":"16","author":"Han","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0009","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(20)32651-9","article-title":"Infectivity of asymptomatic vs symptomatic COVID-19","volume":"397","author":"Sayampanathan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37257","article-title":"Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis","volume":"4","author":"Ma","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.836328","article-title":"Large-scale SARS-CoV-2 antigen testing with real-world specimens","volume":"10","author":"Parikh","year":"2022","journal-title":"Front Public Health"},{"year":"2020","series-title":"Coronavirus Disease 2019 (COVID-19) emergency use authorization for medical devices\u2013in vitro diagnostics EUAs","key":"10.1016\/j.diagmicrobio.2022.115861_bib0012"},{"year":"2020","series-title":"Global research collaboration for infectious disease preparedness. COVID 19: Public Health Emergency of International Concern (PHEIC). global research and innovation forum: towards a research roadmap. Feb. 11-12, 2020","key":"10.1016\/j.diagmicrobio.2022.115861_bib0013"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0014","unstructured":"U.S. Food and Drug Administration. Policy for diagnostic tests for coronavirus disease-2019 during the public health emergency. Available from: www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/policy-diagnostic-tests-coronavirus-disease-2019-during-public-health-emergency. Accessed February 23, 2021."},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0015","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: facilitating diagnostic test availability for asymptomatic testing and sample pooling. FDA statement, 2020. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-facilitating-diagnostic-test-availability-asymptomatic-testing-and. Accessed October 5, 2022."},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0016","unstructured":"U.S.Food and Drug Administration.Coronavirus (COVID-19) Update: FDA takes steps to streamline path for COVID-19 screening tools, provides information to help groups establishing testing programs. FDA statement, 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-takes-steps-streamline-path-covid-19-screening-tools-provides. Accessed October 5, 2022."},{"year":"2020","series-title":"BD SARS-CoV-2 Reagents for BD MAX\u2122 System [package insert]","key":"10.1016\/j.diagmicrobio.2022.115861_bib0017"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0018","unstructured":"U.S. Food and Drug Administration. Template for developers of molecular diagnostic tests. Oct. 6, 2021. Available from:https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas#covid19ivdTemplates. Accessed May 13, 2022."},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0019","unstructured":"U.S.Food and DrugAdministration. Statistical guidance on reporting results from studies evaluating diagnostic tests - guidance for industry and FDA staff. March 2007. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda. Accessed September 26, 2022."},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Statist Assoc"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0021","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1148\/radiol.2015151516","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"277","author":"Bossuyt","year":"2015","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2022.115861_bib0022","article-title":"Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis","volume":"5","author":"Byambasuren","year":"2020","journal-title":"Official J Assoc Med Microbiol Infect Dis Canada"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jmii.2020.05.001","article-title":"A systematic review of asymptomatic infections with COVID-19","volume":"54","author":"Gao","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0024","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/jamainternmed.2020.3862","article-title":"Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea","volume":"180","author":"Lee","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0025","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/cid\/ciaa711","article-title":"The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection","volume":"71","author":"Van Vinh Chau","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0026","doi-asserted-by":"crossref","first-page":"792","DOI":"10.15585\/mmwr.mm7021e3","article-title":"COVID-19 vaccine breakthrough infections reported to CDC - United States, January 1-April 30, 2021","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.diagmicrobio.2022.115861_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01019-21","article-title":"Performance evaluation of the BD SARS-CoV-2 reagents for the BD MAX system","volume":"59","author":"Yanson","year":"2021","journal-title":"J Clin Microbiol"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889322002255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889322002255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:58:17Z","timestamp":1760003897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889322002255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0732889322002255"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115861","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical performance evaluation of BD SARS-CoV-2 reagents for BD MAXTM System in asymptomatic individuals","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115861"}}